Condition: Breast Cancer · Sponsor: D'Or Institute for Research and Education
This is a phase II clinical study testing a more personalized and lighter chemotherapy approach for women with stage I or II triple-negative breast cancer. The treatment is adjusted based on signs from the immune system (called tumor-infiltrating lymphocytes, or TILs) and imaging results during treatment. Patients with stage I triple-negative breast cancer (regardless of TIL levels) and those with stage II disease and high TILs (50% or more) will receive a combination of two chemotherapy drugs (carboplatin and a taxane) for four cycles. If imaging shows the tumor has completely disappeared after this treatment, the patient will go straight to surgery. If the tumor is still visible, the treatment will be strengthened with additional chemotherapy drugs (anthracycline and cyclophosphamide), with or without a medicine called pembrolizumab, which helps the immune system fight cancer. The main goal of the study is to see how many patients have a complete disappearance of the cancer after treatment. Other goals include understanding how imaging results relate to what is found during surgery and tracking how long patients live without the cancer coming back.
This description comes directly from the study's public registry record.
Intituto D'Or de Pesquisa e Ensino São Paulo · pesquisaclinica@idor.org · oncologia.projetos@idor.org
Always discuss trial participation with your own doctor first.
| Instituto D'Or de Pesquisa e Ensino de Brasília | Brasília, Brazil | Recruiting |
| Instituto D'Or de Pesquisa e Ensino de Curitiba | Curitiba, Brazil | Not Yet Recruiting |
| Instituto D'Or de Pesquisa e Ensino do Rio de Janeiro | Rio de Janeiro, Brazil | Recruiting |
| Instituto D'Or de Pesquisa e Ensino de Salvador | Salvador, Brazil | Recruiting |
| Instituto D'Or de Pesquisa e Ensino de São Paulo | São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07074106